Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks

Keyphrases

• Acute Treatment 9%
• Angioedema Attack 100%
• Attack Rate 27%
• Continuous Endpoint 9%
• First Dose 9%
• Hereditary Angioedema 100%
• Intra-patient 18%
• Kappa Coefficient 9%
• Lanadelumab 100%
• Least Mean Square 9%
• Long-term Efficacy 9%
• Onset of Effect 9%
• Overdispersion 9%
• Paired T-test 9%
• Placebo 54%
• Poisson Regression 9%
• Severe Attack 9%
• Steady State 18%
• Time to Onset 9%
• Treatment-related Adverse Events 9%

Medicine and Dentistry

• Adverse Event 9%
• Hereditary Angioedema 100%
• Kappa Statistics 9%
• Lanadelumab 100%
• Least Square Analysis 9%
• Placebo 54%
• Steady State 18%
• Student T Test 9%